Topic: Biology

Researchers at Karolinska Institutet and RIKEN Center for Brain Science found two brain receptors that help regulate the breakdown of amyloid beta, a protein linked to Alzheimer's disease. Their discovery could lead to safer and more affordable treatments.

Alzheimer's disease is the leading cause of dementia, characterized by sticky clumps of amyloid beta forming plaques in the brain. Normally, an enzyme called neprilysin helps clear away amyloid beta. However, neprilysin activity declines with aging and during the progression of the disease.

Researchers at Karolinska Institutet and RIKEN Center for Brain Science discovered that two somatostatin receptors, SST1 and SST4, work together to control neprilysin levels in the hippocampus, a region essential for memory. They found that when both SST1 and SST4 receptors were missing, neprilysin levels dropped, leading to amyloid beta accumulation and memory problems.

The team also tested a compound designed to activate these two receptors. In mice with Alzheimer's-like brain changes, stimulating SST1 and SST4 increased neprilysin levels, reduced amyloid beta buildup, and improved behavior. Importantly, the treatment did not cause serious side effects.

Why It Matters

This discovery could lead to safer and more affordable treatments for Alzheimer's disease, which affects millions of people worldwide. As India's population ages, understanding and addressing this condition is crucial for public health.

Key Facts

• Alzheimer's disease is the leading cause of dementia
• Amyloid beta accumulation is a hallmark of Alzheimer's disease
• Neprilysin helps clear away amyloid beta

Key Terms

Somatostatin receptors

Protein receptors that help regulate neprilysin levels in the brain

Implications

This discovery could lead to safer and more affordable treatments for Alzheimer's disease, which affects millions of people worldwide. As India's population ages, understanding and addressing this condition is crucial for public health.